These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 20380636)

  • 21. Synthesis of terpolymer-lipid encapsulated diruthenium(II,III)-anti-inflammatory metallodrug nanoparticles to enhance activity against glioblastoma cancer cells.
    Alves SR; Colquhoun A; Wu XY; de Oliveira Silva D
    J Inorg Biochem; 2020 Apr; 205():110984. PubMed ID: 31927403
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of a ruthenium(III)/NAMI-A adduct with bovine serum albumin that exhibits a high anti-metastatic activity.
    Liu M; Lim ZJ; Gwee YY; Levina A; Lay PA
    Angew Chem Int Ed Engl; 2010 Feb; 49(9):1661-4. PubMed ID: 20127775
    [No Abstract]   [Full Text] [Related]  

  • 23. Ruthenium(ii) arene NSAID complexes: inhibition of cyclooxygenase and antiproliferative activity against cancer cell lines.
    Mandal P; Kundu BK; Vyas K; Sabu V; Helen A; Dhankhar SS; Nagaraja CM; Bhattacherjee D; Bhabak KP; Mukhopadhyay S
    Dalton Trans; 2018 Jan; 47(2):517-527. PubMed ID: 29235601
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A spectroscopic study of the reaction of NAMI, a novel ruthenium(III)anti-neoplastic complex, with bovine serum albumin.
    Messori L; Orioli P; Vullo D; Alessio E; Iengo E
    Eur J Biochem; 2000 Feb; 267(4):1206-13. PubMed ID: 10672032
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro and in vivo biological activity screening of Ru(III) complexes involving 6-benzylaminopurine derivatives with higher pro-apoptotic activity than NAMI-A.
    Trávníček Z; Matiková-Mal'arová M; Novotná R; Vančo J; Stěpánková K; Suchý P
    J Inorg Biochem; 2011 Jul; 105(7):937-48. PubMed ID: 21536006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Half-Sandwich Ruthenium Arene Complexes Bearing Clinically Approved Drugs as Ligands: The Importance of Metal-Drug Synergism in Metallodrug Design.
    Sumithaa C; Ganeshpandian M
    Mol Pharm; 2023 Mar; 20(3):1453-1479. PubMed ID: 36802711
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In Vivo Performance of a Ruthenium-cyclopentadienyl Compound in an Orthotopic Triple Negative Breast Cancer Model.
    Mendes N; Tortosa F; Valente A; Marques F; Matos A; Morais TS; Tomaz AI; Gärtner F; Garcia MH
    Anticancer Agents Med Chem; 2017; 17(1):126-136. PubMed ID: 27671310
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EPR as a probe of the intracellular speciation of ruthenium(III) anticancer compounds.
    Webb MI; Walsby CJ
    Metallomics; 2013 Dec; 5(12):1624-33. PubMed ID: 24057014
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Arene ruthenium complexes as anticancer agents.
    Süss-Fink G
    Dalton Trans; 2010 Feb; 39(7):1673-88. PubMed ID: 20449402
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design of Ru-arene Complexes for Antitumor Drugs.
    Su W; Li Y; Li P
    Mini Rev Med Chem; 2018; 18(2):184-193. PubMed ID: 28494728
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ruthenium metalation of proteins: the X-ray structure of the complex formed between NAMI-A and hen egg white lysozyme.
    Messori L; Merlino A
    Dalton Trans; 2014 Apr; 43(16):6128-31. PubMed ID: 24553967
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibitory effects of NAMI-A-like ruthenium complexes on prion neuropeptide fibril formation.
    Wang X; Zhu D; Zhao C; He L; Du W
    Metallomics; 2015 May; 7(5):837-46. PubMed ID: 25856332
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Breast Cancer Chemotherapeutic Options: A General Overview on the Preclinical Validation of a Multi-Target Ruthenium(III) Complex Lodged in Nucleolipid Nanosystems.
    Ferraro MG; Piccolo M; Misso G; Maione F; Montesarchio D; Caraglia M; Paduano L; Santamaria R; Irace C
    Cells; 2020 Jun; 9(6):. PubMed ID: 32517101
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ruthenium anticancer drugs and proteins: a study of the interactions of the ruthenium(III) complex imidazolium trans-[tetrachloro(dimethyl sulfoxide)(imidazole)ruthenate(III)] with hen egg white lysozyme and horse heart cytochrome c.
    Casini A; Mastrobuoni G; Terenghi M; Gabbiani C; Monzani E; Moneti G; Casella L; Messori L
    J Biol Inorg Chem; 2007 Nov; 12(8):1107-17. PubMed ID: 17680283
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antineoplastic activity of three ruthenium derivatives against chemically induced colorectal carcinoma in rats.
    Seelig MH; Berger MR; Keppler BK
    J Cancer Res Clin Oncol; 1992; 118(3):195-200. PubMed ID: 1548284
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Axially-modified paddlewheel diruthenium(II,III)-ibuprofenato metallodrugs and the influence of the structural modification on U87MG and A172 human glioma cell proliferation, apoptosis, mitosis and migration.
    Hanif-Ur-Rehman ; Freitas TE; Gomes RN; Colquhoun A; de Oliveira Silva D
    J Inorg Biochem; 2016 Dec; 165():181-191. PubMed ID: 28340940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of a LC method for pharmaceutical quality control of the antimetastatic ruthenium complex NAMI-A.
    Bouma M; Nuijen B; Jansen MT; Sava G; Picotti F; Flaibani A; Bult A; Beijnen JH
    J Pharm Biomed Anal; 2003 Feb; 31(2):215-28. PubMed ID: 12609661
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of Arene Ruthenium Antitumor Complexes.
    Su W; Tang Z; Li P
    Mini Rev Med Chem; 2016; 16(10):787-95. PubMed ID: 27161008
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure-activity relationships for NAMI-A-type complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = imidazole, indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4-triazole): aquation, redox properties, protein binding, and antiproliferative activity.
    Groessl M; Reisner E; Hartinger CG; Eichinger R; Semenova O; Timerbaev AR; Jakupec MA; Arion VB; Keppler BK
    J Med Chem; 2007 May; 50(9):2185-93. PubMed ID: 17402720
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ruthenium complexes as anticancer agents.
    Kostova I
    Curr Med Chem; 2006; 13(9):1085-107. PubMed ID: 16611086
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.